GlaxoSmithKline Pharmaceuticals Limited
Quality (92/100) does the heavy lifting; valuation (21/100) is the drag.
Fair valueOvervaluedOur blended model reads GlaxoSmithKline Pharmaceuticals Limited as a Hold at 45/100. At ₹2,655.4 it trades above our blended DCF and relative-multiples fair value of ₹1,480.2, about 44% downside to that estimate — we read it as overvalued by 44%. On 38.7x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. The price is about 14% below its 52-week high of ₹3,084.09 and 26% above the low of ₹2,103.2. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹2,969.75 implies about 12% upside across 4 analysts. It clears 9 of 13 investability checks, with durability 92, valuation 41 and momentum 78 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,184.16.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-13.90% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 49.1%
- Pass: Low debt (D/E < 0.5): 0.01x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 2%
- Pass: Earnings growing: 6%
- Pass: Net margin ≥ 10%: 27.1%
- Pass: Current ratio > 1.5: 2.03
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 13.54
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter75.6%
- Institutions8.5%
- Public & other15.8%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (49.1%).
- Lightly leveraged balance sheet.
- Healthy profit margin (27.1%).
- Financially solid — Altman Z 13.54.
Bear case
Threats
- Trades ~44% above our estimated fair value.
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for
GlaxoSmithKline Pharmaceuticals Limited — frequently asked questions
Is GlaxoSmithKline Pharmaceuticals Limited a buy, hold or sell?
StocksWizard currently rates GlaxoSmithKline Pharmaceuticals Limited (GLAXO) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is GlaxoSmithKline Pharmaceuticals Limited's fair value?
Our blended DCF and relative-valuation model estimates GlaxoSmithKline Pharmaceuticals Limited's fair value at about ₹1,480.2, versus a current price of ₹2,655.4 — roughly 44% downside. On that basis the stock looks overvalued by 44%.
Is GlaxoSmithKline Pharmaceuticals Limited financially healthy?
GlaxoSmithKline Pharmaceuticals Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has GlaxoSmithKline Pharmaceuticals Limited's share price performed?
GlaxoSmithKline Pharmaceuticals Limited is up 15% over three months, and last traded at ₹2,655.4. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.